NEWEarnings
Absci (ABSI) Stock Price Target Increased on Positive Trial Data
Published on 6/25/2026

AI Summary
H.C. Wainwright has raised its price target for Absci (ABSI) following the release of positive trial data. The new target reflects optimism about the company’s prospects based on the trial performance. While specific figures were not disclosed in the report, this adjustment indicates investor confidence in Absci's future. The price target change could influence investor behavior in the market, potentially affecting Absci's stock performance.
Related News

Earnings
Micron (MU) Shares Surge 18% After Strong Earnings Report
Jun 25

Earnings
Darden Restaurants (DRI) Reports Q4 Earnings, EPS at $3.66 Beats Estimates
Jun 25

Earnings
argenx (ARGX) Stock Rating Reiterated Amid Myositis Trial Update
Jun 25

Earnings
Ionis (IONS) Stock Price Target Raised to $130 Following FDA Approval
Jun 25